anaemia (Nagel et al, 2003) . Moreover, the prevalence of obesity is higher in HbSC patients than in SCA (Chawla et al, 2013) . This non-haematological comorbidity may contribute to cardiac remodelling (Kim et al, 2016) . Echocardiography is currently recommended for routine follow-up of all sickle cell disease patients regardless of genotype (Klings et al, 2014) . However, the echocardiographic features and the cardiac involvement in HbSC versus SCA patients are yet to be described precisely. The aim of this study was to describe cardiac remodelling and its correlates in HbSC patients as compared to patients with SCA and to control subjects.
Methods

Patients
From 1 May 2008 to 31 May 2015, all patients with sickle cell disease referred for echocardiography examination to an experienced physician at the reference centre for sickle cell disease (Tenon Hospital, Paris, France) were retrospectively considered for the study. All patients were referred regardless of signs or symptoms, for routine outpatient evaluation of cardiac function and screening for pulmonary hypertension (Klings et al, 2014) . Patients who had developed acute chest syndrome, vaso-occlusive crisis or an acute complication within the previous 6 weeks and those who had a blood transfusion within the previous 2 weeks were excluded. This was in order to specifically focus on a group of stable patients, free of confounding factors that could impact cardiac function. The other exclusion criteria were more than mild mitral or aortic valve dysfunction, pregnancy and severe kidney failure (glomerular filtration rate <30 ml/min/1Á73 m 2 ). A total of 69 HbSC patients were considered for the study. Of these patients, 2 pregnant women were excluded. From the 67 remaining patients, 60 could be matched for gender and age (AE3 years) on 1:1 basis with 60 stable SCA patients. We also included 60 age and sex-matched healthy subjects as control group. The diagnosis and genotype of sickle cell disease was based on molecular analysis. Clinical and blood samples (i.e. haemoglobin, lactate dehydrogenase, reticulocytes, total bilirubin and serum creatinine) data were collected from patient's records. Laboratory tests were performed within 3 months [median time 11Á5 (0-44) days] of echocardiography evaluation. Elevated blood pressure was defined as a systolic blood pressure >140 mmHg and/or a diastolic blood pressure >90 mmHg. Obesity was defined as a body mass index (BMI) ≥30 kg/m 2 .
This observational study was carried out in accordance with the Helsinki Declaration and approved by the local institutional review board. All enrolled patients gave their consent to participate.
Echocardiography
Transthoracic echocardiography was performed in all patients using the vivid 7 (GE Healthcare; Horten, Norway) or the iE33 (Phillips Medical Systems, Andover, MA,USA) system and transferred to a workstation equipped with the Echopac PC software (GE Vingmed, Horten, Norway) for offline analysis blinded to patient's genotype. All images were acquired according to the guidelines (Lang et al, 2015) and averaged over 3 cardiac cycles.
From M-mode, the following measurements were made at end-diastole: left ventricle (LV) internal diameter and interventricular septal and posterior wall thicknesses. LV mass was calculated using the cube formula and indexed to body surface area (LV mass index, LVMi) (Lang et al, 2015) . LV hypertrophy was defined as LVMi >95 g/m 2 in females and >115 g/m 2 in males (Lang et al, 2015) . Further classification as either concentric hypertrophy (relative wall thickness >0Á42) or eccentric hypertrophy (relative wall thickness ≤0Á42) was made. Moreover, as indexation of LV mass to body surface area was reported to underestimate LV remodelling in overweight patients, LV mass was also normalized for height 2Á7 (de Simone et al, 1992) .
From 2-dimensional mode, LV volumes and LV ejection fraction (LVEF) were measured using Simpson's biplane method. Left atrial (LA) maximal volume was measured by biplane method and indexed to body surface area (Hammoudi et al, 2015; Lang et al, 2015) .
Using the pulsed-wave Doppler mode, early and late peak diastolic velocities of the mitral (E and A) inflow and E-wave deceleration time were measured. From the LV outflow tract dimension and pulsed wave Doppler time-velocity integral, the LV output was calculated and indexed to body surface area (Quiñones et al, 2002) . Using pulsed tissue Doppler imaging, septal and lateral annular mitral plane early diastolic velocities were measured and averaged (e'), the ratio of early diastolic transmitral velocity to tissue velocity (E/e' ratio) was then calculated as an index of LV filling pressure (Nagueh et al, 2009) . Using mitral inflow profile and E/e' ratio, LV diastolic function was categorized as normal or abnormal (Sachdev et al, 2007) .
From continuous-wave Doppler, peak TRV was recorded in multiple views and the highest level of velocity was selected and used to estimate pulmonary artery systolic pressure. According to Sickle Cell Disease guidelines (Klings et al, 2014) , elevated pulmonary systolic pressure was defined as TRV >2Á5 m/s and severe elevation as TRV ≥3 m/s.
Statistical analysis
All quantitative data are expressed as median and interquartile range (IQR); qualitative data are expressed as counts and percentages. Comparisons between continuous data were made using the Kruskal-Wallis test. The Fisher's exact test was used to compare categorical data. Correlations were evaluated using the Pearson test. To detect a correlation >0Á4 between haematological variables and echocardiography parameters with 90% power and a 2-sided alpha level of 0Á05, a sample size of 60 HbSC patients was calculated.
Using logistic regression analysis we further investigated, in both genotypes, the clinical and biological correlates of LV Cardiac Manifestations and Sickle Cell Disease Genotype ª 2018 John Wiley & Sons Ltd diastolic dysfunction and elevated pulmonary systolic pressure as established risk factors of mortality in sickle cell disease patients (Gladwin et al, 2004; Sachdev et al, 2007; Klings et al, 2014) . The variables included in the analysis were those associated with heart involvement in the univariate analysis with P < 0Á10. MedCalc version 14.12.0 (MedCalc Software, Ostend, Belgium) was used for calculation. A P < 0Á05 indicated statistical significance.
Results
Population
The clinical characteristics of the study population are summarized in Table I . The median age of HbSC patients was 31 years (IQR, 24-37) and 25 (42%) patients were male. The 3 groups were matched for age and gender. While heart rate was similar between the 3 groups, diastolic blood pressure was lower in SCA patients. In the HbSC population the prevalence of obesity was higher compared to SCA patients and controls. HbSC patients had higher haemoglobin levels and lower haemolysis parameters compared to SCA. A similar proportion of patients had a history of pulmonary embolism: 4 (7%) and 3 (5%) patients for HbSC and SCA respectively (P = 0Á99).
Echocardiography parameters
The echocardiographic findings of SCA as compared to HbSC disease and controls are reported in Table II . LV volumes and mass were greater in both genotypes compared to controls. However, while LV hypertrophy was observed only in 3 (5%) HbSC patients, this condition was diagnosed in 27 (45%) patients with SCA (P < 0Á0001). The LV hypertrophy was mainly eccentric; only one SCA patient had concentric hypertrophy (Table II) . Importantly, LV mass was greater in SCA compared to HbSC, regardless of the indexing method (i.e. body size area or height 2Á7 ).
Compared to controls, the LA volume index was higher in both genotypes of sickle cell disease patients. However, while LA size was dramatically increased in SCA, LA volume index was mildly elevated in HbSC (Table II) . Only 1 (2%) patient with HbSC disease had a severe LA dilation (>48 ml/m 2 ) (Lang et al, 2015) , but this condition was present in 32 (56%) SCA patients (P < 0Á0001). While cardiac index was similar in HbSC genotype compared to controls, 3Á1 [2Á7-3Á5] and 3Á0 [2Á6-3Á3] l/min/m 2 respectively, P = 0Á40; SCA patients exhibited a high output state, 4Á2 [3Á6-4Á7] l/min/m 2 , P < 0Á0001. LV systolic function, as assessed by LVEF was similar between the 3 groups. However, both genotypes exhibited LV diastolic dysfunction and had a higher E/e' ratio compared to controls (Table II) . TRV was similar in HbSC patients compared to controls, 2Á2 [2Á1-2Á4] and 2Á2 [2Á1-2Á3] m/s respectively, P = 0Á10. In contrast, SCA patients exhibited a higher level of pulmonary systolic pressure, 2Á6 [2Á3-2Á7] m/s, P < 0Á0001. Although, no control and no HbSC patient had a severe elevation of TRV (≥3 m/s), this condition was observed in 3 (5%) patients with SCA.
Correlates of heart remodeling according to sickle cell disease genotype
The univariate relationship between haematological variables and echocardiography parameters in both genotypes are presented in Table III . Cardiac remodelling in SCA patients was related to the severity of anaemia and haemolysis (i.e. lactate dehydrogenase level); in contrast, heart involvement in HbSC disease was mostly not related to the haematological disorders. In the latter genotype, only LA volume index was weakly correlated to haemoglobin level (r = À0Á28, P = 0Á04).
In the HbSC population, the haematological variables were not linked to LV diastolic dysfunction nor related to elevated pulmonary pressure (Table IV) . LV diastolic dysfunction was observed in 4 of the 7 (57%) patients with arterial hypertension and in only 3 of the 53 (6%) other patients (P = 0Á002). In logistic regression analysis, the LV diastolic dysfunction remained independently related to arterial hypertension (odds ratio = 9Á1, P = 0Á04). The 4 HbSC patients with TRV > 2Á5 m/s had higher BMI compared to the rest of the HbSC population [30 (30-32) and 23 (21-26) kg/m 2 respectively, P = 0Á002]. All HbSC patients with elevated pulmonary systolic pressure were obese. In logistic regression analysis, the BMI was the only independent determinant of TRV > 2Á5 m/s (odds ratio = 1Á87, P = 0Á01).
In SCA patients, LV diastolic dysfunction and elevated pulmonary systolic pressure were not related to arterial hypertension nor to BMI (Table V) . In logistic regression analysis, the haemoglobin level was an independent determinant of TRV > 2Á5 m/s (odds ratio = 0Á63, P = 0Á02).
Discussion
Our study describes the differences in heart involvement in the two most common genotypes of sickle cell disease. Compared to SCA patients, HbSC patients had a relatively mild left heart remodelling, with uncommon LV hypertrophy and moderate LA dilation. Cardiac index and systolic pulmonary pressures were similar in HbSC patients and controls, while SCA patients exhibited a high cardiac output state and high pulmonary pressures. Interestingly, both sickle cell disease genotypes exhibited LV diastolic dysfunction and had higher LV filling pressures compared to controls. However, cardiac involvement in SCA was related to the severity of the haematological disorders, while heart remodelling in HbSC disease was related to overweight and/or arterial hypertension comorbidities, but not to anaemia and haemolysis.
SCA, due to a homozygous mutation of HBB, resulting in a mutant haemoglobin S, is the most common genotype of sickle cell disease. The cardiac remodelling associated with this genotype has been extensively studied (Gladwin & Sachdev, 2012; Voskaridou et al, 2012; Hammoudi et al, 2014 Hammoudi et al, , 2015 Damy et al, 2016) . According to our findings, heart involvement is frequent and mainly related to haematological variables in this population of patients (Damy et al, 2016) . Moreover, pulmonary systolic pressure, assessed by TRV, as well as LV diastolic dysfunction diagnosed by ultrasound are risk factors associated with mortality (Gladwin et al, 2004; Sachdev et al, 2007; Caughey et al, 2015; Damy et al, 2016; Gladwin, 2016) and echocardiography is part of the routine follow-up of SCA patients (Klings et al, 2014) . HbSC disease, which results from the combination of haemoglobin S with haemoglobin C caused by a compound heterozygosity for two different HBB mutations, represents the second most common genotype of sickle cell disease, accounting for up to a quarter of the cases Weatherall, 2010; Sachdev et al, 2011; Leite et al, 2012; Saraf et al, 2014) and affecting approximately 55000 newborns every year worldwide (Weatherall, 2010) . However, the cardiac features associated with HbSC disease are mostly unknown as the studies published so far investigated mostly SCA genotype ( Figure S1 , Table SI) . In these studies, HbSC patients were either not enrolled (Lee et al, 2009; Desai et al, 2013; Poludasu et al, 2013; Di Maria et al, 2015) or pooled with SCA patients, representing only a minority of the study population (Platt et al, 1994; Gladwin et al, 2004; De Castro et al, 2008; Dham et al, 2009; Cabrita et al, 2013) . Considering the well-established pathophysiological and clinical profile differences between the SCA and HbSC genotypes (Lionnet et al, 2012; Saraf et al, 2014; Gualandro et al, 2015) , we hypothesized that the cardiac phenotype and its correlates of the two disease forms would be different. Recently, in an additional analysis of two cohorts of sickle cell disease patients, a lower prevalence of pulmonary hypertension and less pronounced LV remodelling were reported in HbSC disease compared to SCA patients (Saraf et al, 2014) . However, in that study, patients were not matched for age and gender, there was no control group and the determinants of cardiac remodelling in HbSC patients were not investigated (Saraf et al, 2014) .
As previously described (Nagel et al, 2003; Lionnet et al, 2012) , HbSC patients in our study had a relatively low haemolysis rate and only mild anaemia compared to those with SCA. The higher prevalence of obesity in non-homozygous forms of sickle cell disease has been previously reported, raising concerns about specific morbidity related to this condition (Chawla et al, 2013) . LV hypertrophy and diastolic dysfunction are well established in patients with arterial hypertension (Marwick et al, 2015; Kim et al, 2016) .
Compared to SCA, a lower prevalence of pulmonary hypertension in patients with HbSC was previously reported (Klings et al, 2014; Saraf et al, 2014) . However, the screening of this complication by echocardiography is still currently recommended in all sickle cell disease patients, regardless of genotype (Machado & Gladwin, 2010; Klings et al, 2014; Mehari & Klings, 2016) . In the present study we showed that the pulmonary artery systolic pressure of HbSC patients is similar to a population of control subjects. Moreover, in this genotype, we observed that BMI is independently related to TRV, as reported in patients without haematological disorders (D'Andrea et al, 2014). The well documented better prognosis of HbSC disease patients compared to patients with SCA (Platt et al, 1994) might be partially related to the better cardiovascular status of HbSC patients. There is few data regarding invasive haemodynamics in patients with HbSC. In one study, SCA and HbSC patients were enrolled and pooled in the analyses (Mehari et al, 2012) . After baseline non-invasive evaluation, right heart catheterization was performed in high-risk patients (n = 84) including only 14 with HbSC. However, that study was not designed to compare SCA and HbSC pulmonary haemodynamics. (Mehari et al, 2012) . Despite the reassuring cardiovascular data provided by our study, one should keep in mind that HbSC disease should not be considered as a benign disease, as unpredictable lifethreatening complications might occur (Lionnet et al, 2012) . In particular, the risk of venous thromboembolism is high in adult patients with sickle cell disease (van Hamel Parsons et al, 2016; Mehari & Klings, 2016) . This is consistent with the relatively high prevalence of history of pulmonary embolism observed in our study. Considering the severity of pulmonary embolism, this complication should be generally suspected in case of cardiovascular symptoms.
Clinical implications
Our findings may help clinicians in charge of the follow-up of sickle cell disease patients. For the haematologist, our data suggest that echocardiography may not be needed in all adult patients with HbSC disease and could be limited to patients with symptoms or non-haematological comorbidities, such as arterial hypertension or obesity (Marwick et al, 2015) . The clinician should consider the patient's genotype in regards to the echocardiographic findings. A high pulmonary pressure in a patient with HbSC disease should raise the hypothesis of a post-embolic mechanism. Finally, HbSC patients should not be pooled with SCA patients in clinical studies with regard to cardiac evaluation or clinical outcome.
Study limitations
Several limitations need to be acknowledged. First, this is a retrospective study. Second, we used TRV for the assessment of pulmonary systolic pressure and this parameter was not available in 5 (8%) HbSC patients. Comparative evaluations of HbSC versus SCA pulmonary haemodynamics, using right heart catheterization as a gold standard (Parent et al, 2011; Mehari et al, 2012) , are lacking and require further investigations. Finally, the evaluation of clinical outcome according to patient genotype was not the goal of our study and was not performed.
Conclusions
The findings of this study support the conclusion that the cardiac phenotype and its determinants are different in the 2 most common genotypes of sickle cell disease. Compared to SCA, HbSC patients show mild heart remodelling, mainly related to overweight and/or arterial hypertension comorbidities and not to anaemia and haemolysis. These findings may alter the indication for echocardiography in this population.
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